Challenges in Early Drug Development Explored In New InnaPhase White Paper.PHILADELPHIA--(BUSINESS WIRE)--Nov. 4, 1999-- InnaPhase Corporation, a leader in the creation of software tools and technology for early drug development teams, has recently published a White Paper that explores managing, analyzing and reporting Pharmacokinetic and Pharmacodynamic data with an enterprise software solution. Written by InnaPhase's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Peter Ryan People named Peter Ryan include:
tr.v. en·ti·tled, en·ti·tling, en·ti·tles 1. To give a name or title to. 2. To furnish with a right or claim to something: , "Challenges in Early Drug Development." "Rapid evolution in techniques and technologies has taken place in many areas of pharmaceutical research and development, with drug development pipelines being filled beyond capacity by novel drug discovery approaches," said Ryan. "Pharmaceutical companies are under competitive pressures to grow, while receiving closer scrutiny from regulatory agencies regulatory agency Independent government commission charged by the legislature with setting and enforcing standards for specific industries in the private sector. The concept was invented by the U.S. . The result has been a dramatic increase in the number of pre-clinical and clinical studies conducted to support a new drug submission. "Historically, software providers for the pharmaceutical research and development arena have been fragmented or lack sufficient global understanding of the early development processes to be able to offer integrated solutions," Ryan said. "Current technologies in early development fail to address the reality that data produced during the various development phases, must be integrated at several levels in order to provide accurate information for reporting evidence of safety and efficacy to both management and regulatory agencies." Ryan's White Paper has been developed in support of InnaPhase's new EP1 TM System. The EP1 system is the first commercially available GLP See gateway location protocol. compliant Pharmacokinetic-Pharmacodynamic database management, analysis and simulation software Simulation software is based on the process of imitating a real phenomenon with a set of mathematical formulas. It is, essentially, a program that allows the user to observe an operation through simulation without actually running the program. program in the world. As developed by InnaPhase, EP1 offers significant productivity improvements for scientific teams within pharmaceutical and contract research organizations, therefore enhancing the early drug development process. InnaPhase's EP1 system provides: centralized cen·tral·ize v. cen·tral·ized, cen·tral·iz·ing, cen·tral·iz·es v.tr. 1. To draw into or toward a center; consolidate. 2. data management via Oracle; intelligent data import and export components; a flexible cross-study data mining tool; and a powerful industry standard PK/PD PK/PD Pharmacokinetic/Pharmacodynamic analysis, simulation and reporting module (KINETICA). Full GLP compliance across the system is managed by a security and audit layer which communicates with a set of robust quality assurance tools, allowing auditors to perform full data tracking throughout a study's life in the system. EP1 is unique in the industry. No other product offering currently available can provide the level of scientific data analysis tools, including non-compartmental and compartmental analyses (standard and population), in a GLP compliant secure database environment. For further information on EP1 System, or to receive a copy of Ryan's White Paper, contact InnaPhase at 215/299-7400. About InnaPhase Corporation InnaPhase Corporation (http://www.innaphase.com) provides innovative technology solutions for early drug development teams. With more than 800 client organizations in 45 countries, the company's software technologies allow clients to maximize their drug development pipeline. InnaPhase leverages scientific experience with advanced software and database technologies to provide specialized systems that are powerful, yet easy to use, and highly scalable. In the race to reduce the time and cost for drug development, InnaPhase's fully integrated and scalable set of database technologies provides a competitive edge. With offices in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , France and England, InnaPhase is rapidly becoming the industry standard in software applications for pre-clinical and clinical pharmacology Clinical pharmacology is the science of drugs and their clinical use. It is underpinned by the basic science of pharmacology, with added focus on the application of pharmacological principles and methods in the real world. . The InnaPhase name and design is a registered trademark. EP1 and Kinetica are trademarks of InnaPhase Corporation. All other company names and products are trademarks or registered trademarks of their respective companies. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion